newsfilter
← Latest News
GlobeNewswire·

Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Following constructive FDA feedback, Seres is finalizing its SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for the